FibroGen Inc (NASDAQ:FGEN) was the recipient of a significant increase in short interest in October. As of October 31st, there was short interest totalling 4,370,000 shares, an increase of 5.8% from the September 30th total of 4,130,000 shares. Approximately 5.8% of the shares of the company are short sold. Based on an average trading volume of 699,800 shares, the short-interest ratio is currently 6.2 days.
In related news, insider K Peony Yu sold 3,419 shares of the stock in a transaction on Monday, September 16th. The stock was sold at an average price of $40.92, for a total value of $139,905.48. Following the sale, the insider now owns 175,240 shares in the company, valued at $7,170,820.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Christine Chung sold 5,625 shares of the stock in a transaction on Thursday, November 14th. The stock was sold at an average price of $34.74, for a total value of $195,412.50. Following the completion of the sale, the senior vice president now owns 145,253 shares in the company, valued at approximately $5,046,089.22. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 92,381 shares of company stock worth $3,839,495. Company insiders own 8.96% of the company’s stock.
Several hedge funds have recently modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in FibroGen by 8.7% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,726 shares of the biopharmaceutical company’s stock worth $175,000 after buying an additional 378 shares during the period. Doheny Asset Management CA boosted its holdings in FibroGen by 1.6% in the 2nd quarter. Doheny Asset Management CA now owns 36,471 shares of the biopharmaceutical company’s stock worth $1,648,000 after buying an additional 586 shares during the period. State Board of Administration of Florida Retirement System boosted its holdings in FibroGen by 1.8% in the 2nd quarter. State Board of Administration of Florida Retirement System now owns 40,364 shares of the biopharmaceutical company’s stock worth $1,824,000 after buying an additional 720 shares during the period. Zacks Investment Management boosted its holdings in FibroGen by 2.8% in the 2nd quarter. Zacks Investment Management now owns 26,642 shares of the biopharmaceutical company’s stock worth $1,204,000 after buying an additional 738 shares during the period. Finally, Envestnet Asset Management Inc. lifted its stake in FibroGen by 4.1% in the 3rd quarter. Envestnet Asset Management Inc. now owns 22,334 shares of the biopharmaceutical company’s stock worth $826,000 after purchasing an additional 881 shares in the last quarter. 69.03% of the stock is owned by hedge funds and other institutional investors.
Shares of NASDAQ FGEN traded up $2.01 during trading hours on Friday, hitting $36.99. The company’s stock had a trading volume of 1,002,000 shares, compared to its average volume of 1,180,421. The company has a debt-to-equity ratio of 0.07, a quick ratio of 9.71 and a current ratio of 9.01. FibroGen has a 12 month low of $32.33 and a 12 month high of $61.23. The stock has a market cap of $3.05 billion, a price-to-earnings ratio of -35.91 and a beta of 1.84. The business has a 50-day simple moving average of $38.31 and a 200-day simple moving average of $41.63.
FibroGen (NASDAQ:FGEN) last posted its earnings results on Monday, November 11th. The biopharmaceutical company reported ($0.57) EPS for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.02. FibroGen had a net margin of 11.81% and a return on equity of 7.33%. The business had revenue of $33.17 million during the quarter, compared to the consensus estimate of $31.61 million. During the same quarter in the previous year, the firm posted ($0.50) EPS. The firm’s revenue was up 14.3% on a year-over-year basis. On average, equities research analysts forecast that FibroGen will post -0.16 EPS for the current year.
FibroGen Company Profile
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
See Also: What is the Quick Ratio?
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.